On February 3, 2014, Endo successfully completed its acquisition of specialty generics company Boca Pharmacal.
On February 3, 2014, Endo completed its divestiture of HealthTronics to Altaris Capital Partners, LLC.
On February 28, 2014, Endo completed its acquisition of Paladin Labs, a leading Canada-based specialty pharmaceutical company.
On February 28, 2014, Endo and Paladin Labs came together under Endo International plc. Endo established new global headquarters in Dublin, Ireland.
In March 2014, U.S. FDA approved AVEED® (Testosterone Undecanoate) injectable testosterone replacement therapy for men living with hypogonadism, or Low-T
On July 24, 2014, Endo completed its acquisition of Grupo Farmaceutico Somar® (SOMAR), a leading, privately owned specialty pharmaceuticals company based in Mexico City.
On August 6, 2014, Endo completed its acquisition of DAVA Pharmaceuticals, Inc., a privately-held company specializing in generic pharmaceuticals.